Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming

This publication has 59 references indexed in Scilit:

• Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA_1c Levels
  JAMA Internal Medicine, 2023
• Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
  JAMA Network Open, 2023
• MiR-20a-5p alleviates kidney ischemia/reperfusion injury by targeting ACSL4-dependent ferroptosis
  American Journal of Transplantation, 2023
• Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging
  Acta Pharmaceutica Sinica B, 2021
• The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
  Kidney International, 2020
• The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
  Kidney International, 2020
• Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
  Diabetes Research and Clinical Practice, 2019
• Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis
  Cell Metabolism, 2019
• SIRT3 Mediates Multi-Tissue Coupling for Metabolic Fuel Switching
  Cell Metabolism, 2015
• SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage
  Free Radical Biology and Medicine, 2013